跳至主要内容
临床试验/CTIS2023-506227-29-00
CTIS2023-506227-29-00进行中(未招募)1 期

M24-427

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 220 人开始时间: 2024年4月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
220

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

进行中(未招募)
1 期
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulationsVasomotor symptoms as a sex hormone-dependent disorder in women and menMedDRA version: 20.0Level: LLTClassification code: 10067819Term: Andropausal symptoms Class: 10014698MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10027304Term: Menopausal symptoms Class: 100000004872
CTIS2023-503968-16-00Bayer Consumer Care AG16
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin deltaInfertility in women undergoing assisted reproductive technologies (ART)
CTIS2023-508149-42-00Ferring Pharmaceuticals A/S200
进行中(未招募)
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.Bipolar disorder, Epilepsy
CTIS2024-513106-62-00Sun Pharmaceutical Industries Limited30
招募中
1 期
A study to learn if UCB3101 is safe and how it moves through the body of healthy participantsHealthy ParticipantsMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848
CTIS2023-504586-24-00CB Biopharma88
进行中(未招募)
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaRelapsed or Refractory Multiple Myeloma (R/R MM)MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104
CTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55